MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 54c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of ($0.62), $0.54 worse than the analyst estimate of ($0.08).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Nucor projects Q3 2026 earnings above prior year, below estimates
• Nomad Power Solutions files SEC disclosure after merger completion
• McDonald's (MCD) Raises Quarterly Dividend 3.8% to $1.93; 3.1% Yield